M&A / Deals Roche and C4 Therapeutics to advance degrader-antibody conjugates research Pharmaceutical TechnologyRoche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaceutical Technology Roche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer. M&A / DealsOncologyRead full story Post navigation Previous: Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisationNext: Roche places a $1bn bet on C4T degrader-antibody conjugates Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
